Literature DB >> 19380601

Comparison of the pharmacodynamics of biapenem in bronchial epithelial lining fluid in healthy volunteers given half-hour and three-hour intravenous infusions.

Eiki Kikuchi1, Junko Kikuchi, Yasuyuki Nasuhara, Satoshi Oizumi, Akitoshi Ishizaka, Masaharu Nishimura.   

Abstract

The time above the MIC (T>MIC) is the pharmacokinetic/pharmacodynamic (PK/PD) parameter that correlates with the therapeutic efficacy of beta-lactam antibiotics. A prolonged infusion can provide plasma drug concentrations that remain above the MIC for a long period. The objective of this study was to compare the PK/PD parameters in bronchial epithelial lining fluid (ELF) of biapenem given as 0.5-h and 3-h infusions by using bronchoscopic microsampling (BMS). Six healthy adult volunteers received 0.5-h and 3-h infusions of 0.3 g of biapenem with a washout interval. BMS was performed repeatedly from 0.5 to 24 h after biapenem administration in order to determine the pharmacokinetics in bronchial ELF. The subjects received intravenous biapenem with the same regimens again and then underwent bronchoalveolar lavage (BAL) at the end of infusion in order to determine the concentration of the drug in alveolar ELF. The percentages (means +/- standard deviations) of T>MIC in bronchial ELF at MICs from 0.25 to 4 microg/ml ranged from zero to 34.6% +/- 5.2% after the 0.5-h infusion and from 5.1% +/- 5.6% to 52.2% +/- 17.0% after the 3-h infusion. The percentage of T>MIC in bronchial ELF after the 3-h infusion tended to be higher than that after the 0.5-h infusion. The concentrations of the drug in alveolar ELF after 0.5-h and 3-h infusions were 3.5 +/- 1.2 microg/ml and 1.3 +/- 0.3 microg/ml, respectively. The present results support the use of prolonged infusions of beta-lactam antibiotics and may provide critical information for successful treatment of lower respiratory tract infections based on PK/PD parameters in bronchial ELF.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19380601      PMCID: PMC2704648          DOI: 10.1128/AAC.01578-08

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  31 in total

1.  Concentrations of single-dose meropenem (1 g iv) in bronchoalveolar lavage and epithelial lining fluid.

Authors:  B Allegranzi; A Cazzadori; G Di Perri; S Bonora; M Berti; L Franchino; A Biglino; A Cipriani; E Concia
Journal:  J Antimicrob Chemother       Date:  2000-08       Impact factor: 5.790

Review 2.  The hidden impact of antibacterial resistance in respiratory tract infection. Re-evaluating current antibiotic therapy.

Authors:  W A Craig
Journal:  Respir Med       Date:  2001-06       Impact factor: 3.415

3.  Contributions of bronchoscopic microsampling in the supplemental diagnosis of small peripheral lung carcinoma.

Authors:  Masazumi Watanabe; Akitoshi Ishizaka; Eiji Ikeda; Akira Ohashi; Koichi Kobayashi
Journal:  Ann Thorac Surg       Date:  2003-11       Impact factor: 4.330

4.  Prevention of resistance: a goal for dose selection for antimicrobial agents.

Authors:  G L Drusano
Journal:  Clin Infect Dis       Date:  2003-01-15       Impact factor: 9.079

5.  Bronchoscopic microsampling method for measuring drug concentration in epithelial lining fluid.

Authors:  Koichi Yamazaki; Shigeaki Ogura; Akitoshi Ishizaka; Toshinari Oh-hara; Masaharu Nishimura
Journal:  Am J Respir Crit Care Med       Date:  2003-08-06       Impact factor: 21.405

6.  Comparison of the pharmacodynamics of meropenem in healthy volunteers following administration by intermittent infusion or bolus injection.

Authors:  Sutep Jaruratanasirikul; Somchai Sriwiriyajan
Journal:  J Antimicrob Chemother       Date:  2003-08-13       Impact factor: 5.790

7.  Comparative in-vitro activity of carbapenem antibiotics against respiratory pathogens isolated between 1999 and 2000.

Authors:  A Watanabe; Y Tokue; H Takahashi; T Kikuchi; T Kobayashi; K Gomi; S Fujimura; S Yasui; Y Murayama; T Nukiwa
Journal:  J Infect Chemother       Date:  2001-12       Impact factor: 2.211

8.  New bronchoscopic microsample probe to measure the biochemical constituents in epithelial lining fluid of patients with acute respiratory distress syndrome.

Authors:  A Ishizaka; M Watanabe; T Yamashita; Y Ogawa; H Koh; N Hasegawa; H Nakamura; K Asano; K Yamaguchi; M Kotani; T Kotani; H Morisaki; J Takeda; K Kobayashi; S Ogawa
Journal:  Crit Care Med       Date:  2001-04       Impact factor: 7.598

Review 9.  Biapenem.

Authors:  Caroline M Perry; Tim Ibbotson
Journal:  Drugs       Date:  2002       Impact factor: 9.546

10.  Pharmacokinetics of clarithromycin in bronchial epithelial lining fluid.

Authors:  Eiki Kikuchi; Koichi Yamazaki; Junko Kikuchi; Naoki Hasegawa; Satoru Hashimoto; Akitoshi Ishizaka; Masaharu Nishimura
Journal:  Respirology       Date:  2008-03       Impact factor: 6.424

View more
  8 in total

Review 1.  Penetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antibacterial agents.

Authors:  Keith A Rodvold; Jomy M George; Liz Yoo
Journal:  Clin Pharmacokinet       Date:  2011-10       Impact factor: 6.447

2.  A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Biapenem in Healthy Adult Subjects.

Authors:  David C Griffith; Elizabeth E Morgan; Michael N Dudley; Jeffery S Loutit
Journal:  Antimicrob Agents Chemother       Date:  2021-03-08       Impact factor: 5.191

3.  Population pharmacokinetics and Monte Carlo dosing simulations of meropenem during the early phase of severe sepsis and septic shock in critically ill patients in intensive care units.

Authors:  Sutep Jaruratanasirikul; Suriyan Thengyai; Wibul Wongpoowarak; Thitima Wattanavijitkul; Kanyawisa Tangkitwanitjaroen; Waroonrat Sukarnjanaset; Monchana Jullangkoon; Maseetoh Samaeng
Journal:  Antimicrob Agents Chemother       Date:  2015-03-09       Impact factor: 5.191

4.  Pharmacokinetics and pharmacodynamics of oral and intravenous cefetamet in dog.

Authors:  Wei Wang; Xiao-Mao Zhu; Chun-Mei Wang; Si Gou; Zhong-Hua Chen; Yuan Zhao
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2014-07-13       Impact factor: 2.441

5.  Applications of minimal physiologically-based pharmacokinetic models.

Authors:  Yanguang Cao; William J Jusko
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-11-23       Impact factor: 2.745

6.  In vitro and in vivo activity of biapenem against drug-susceptible and rifampicin-resistant Mycobacterium tuberculosis.

Authors:  Amit Kaushik; Nicole C Ammerman; Rokeya Tasneen; Elizabeth Story-Roller; Kelly E Dooley; Susan E Dorman; Eric L Nuermberger; Gyanu Lamichhane
Journal:  J Antimicrob Chemother       Date:  2017-08-01       Impact factor: 5.790

7.  Absorption of Nasal and Bronchial Fluids: Precision Sampling of the Human Respiratory Mucosa and Laboratory Processing of Samples.

Authors:  Ryan S Thwaites; Hannah C Jarvis; Nehmat Singh; Akhilesh Jha; Andy Pritchard; Hailing Fan; Tanushree Tunstall; Joan Nanan; Simon Nadel; Onn Min Kon; Peter J Openshaw; Trevor T Hansel
Journal:  J Vis Exp       Date:  2018-01-21       Impact factor: 1.355

Review 8.  Pharmacokinetics-pharmacodynamics issues relevant for the clinical use of beta-lactam antibiotics in critically ill patients.

Authors:  Rui Pedro Veiga; José-Artur Paiva
Journal:  Crit Care       Date:  2018-09-24       Impact factor: 9.097

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.